Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96KN2
UPID:
CNDP1_HUMAN
Alternative names:
CNDP dipeptidase 1; Carnosine dipeptidase 1; Glutamate carboxypeptidase-like protein 2; Serum carnosinase
Alternative UPACC:
Q96KN2; Q14D40; Q17S05; Q2TBG0; Q6UWK2; Q9BT98
Background:
Beta-Ala-His dipeptidase, also known as CNDP dipeptidase 1, Carnosine dipeptidase 1, Glutamate carboxypeptidase-like protein 2, and Serum carnosinase, plays a crucial role in the metabolism of carnosine and anserine. It catalyzes the peptide bond hydrolysis in Xaa-His dipeptides, with a preference for beta-alanyl-L-histidine (carnosine) and beta-alanyl-3-methyl-histidine (anserine), showcasing its specificity and importance in biochemical pathways.
Therapeutic significance:
Understanding the role of Beta-Ala-His dipeptidase could open doors to potential therapeutic strategies, offering insights into novel approaches for targeting metabolic pathways and disorders.